The state of California currently has 18 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including Los Angeles, San Francisco, San Diego and Sacramento.
Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
NCT06162884
Recruiting
This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD). The purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc/ machine learning (AI/ML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-te... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: UCLA, Los Angeles, California
Conditions: Pulmonary Fibrosis
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: University of Southern California, Los Angeles, California +4 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF
NCT06331624
Recruiting
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An early-stage patient... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
03/05/2025
Locations: Newport Native MD, Inc., Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis, IPF
Register for Updates
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
NCT05195918
Recruiting
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
10/15/2024
Locations: UCSF Parnassus, San Francisco, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Atezolizumab for Idiopathic Pulmonary Fibrosis
NCT05515627
Recruiting
The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
08/21/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Investigate Leramistat in Patients With IPF
NCT05951296
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: UCSF Fresno, Fresno, California
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates